Skip to Content

Search results for “metformin

  • Aging and Lifespan

    Metformin for Aging in General?

    Here’s an interesting report in the Wall Street Journal on plans to run a large clinical trial with metformin. That compound has a lot of effects, and many of them seem as if they could be beneficial in an aging population. Dr. Barzilai expects to enroll more than 1,000 elderly participants in the randomized, controlled… Read More
  • Cancer

    More on Metformin and Cancer (and Alzheimer’s)

    Metformin: what a weird compound it is. Very small, very polar, the sort of thing you’d probably cross off your list of screening hits. But it’s been taken by untold millions of diabetics (and made untold billions of dollars in the process), because it really does reduce glucose levels. It does so though mechanisms that… Read More
  • Cancer

    Metformin Against Cancer?

    It’s always good to hear about an older compound that may be doing good things that we didn’t realize. The current example is metformin, the diabetes drug known to many by its brand name Glucophage, but a generic compound for some years now. Evidence has recently been accumulating that patients taking it over the long… Read More
  • Cardiovascular Disease

    AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking about anything to do with the response to levels of fuel like glucose or fatty acids and determination of their downstream fates, then AMPK is almost certainly crucial. Activating the enzyme se… Read More
  • Aging and Lifespan

    The First Real Anti-Aging Trial in Humans

    I’ve mentioned the proposed clinical trial with metformin as a general anti-aging therapy. Here’s a profile of Nir Barzilai, the principle investigator for it. Choosing metformin was as much about going in with a drug that has a very clean safety profile as anything else: “There’s nothing we don’t know about metformin,” Barzilai… Read More
  • Patents and IP

    The Problem With Patents

    Fair warning: this is a post about patents and IP. I say that because in the past, I’ve practically been able to see the readers fleeing in real time when such things come up. Two or three of them in a row, and there would probably be nobody left around at all. But it’s a… Read More
  • Aging and Lifespan

    Aging As a Disease

    I’ve mentioned numerous times around here that therapies directed against aging in general have a rough regulatory outlook. The FDA, in general, has not considered aging a disease by itself, but rather the baseline against which disease (increasingly) appears. This has meant that companies with ideas for anti-aging therapies have had to work… Read More
  • Chemical News

    The Smallest Drugs

    Here is the updated version of the “smallest drugs” collection that I did the other day. Here are the criteria I used: the molecular weight cutoff was set, arbitrarily, at aspirin’s 180. I excluded the inhaled anaesthetics, only allowing things that are oils or solids in their form of use. As a small-molecule organic chemist… Read More
  • Business and Markets

    Salary Freeze at Lilly

    We now return to our regularly schedule program around here – or at least, Eli Lilly is now returning to theirs. The company announced that they’re freezing salaries for most of the work force, in an attempt to save hundreds of millions of dollars in advance of their big patent expirations. Some bonuses will be… Read More
  • Clinical Trials

    That $43 Million R&D Figure

    One of the readers in the comments section to the last post noticed Rebecca Warburton trying to clarify that absurd $43-million-per-drug R&D figure. You’ll find her response in the comments section to the Slate piece that brought this whole study so much attention. Says Warburton: . . .Our estimate of $59 million is the median… Read More
12